Methylation of CLDN6, FBN2, RBP1, RBP4, TFPI2, and TMEFF2 in esophageal squamous cell carcinoma

Oncology Reports

Volumn 21, Issue 4, 2009, Pages 1067-1073

  Tsunoda, Shigeru ^a,b   Smith, Eric ^a   De Young, Neville J ^a   Wang, Xian ^a   Tian, Zi Qing ^c   Liu, Jun Feng ^c   Jamieson, Glyn G ^a   Drew, Paul A ^d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b KYOTO UNIVERSITY   (Japan)

^c HEBEI MEDICAL UNIVERSITY   (China)

^d FLINDERS UNIVERSITY   (Australia)

Author keywords

CLDN6; Esophageal cancer; FBN2; Methylation; RBP1; RBP4; TFPI2; TMEFF2

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MESSENGER RNA; PROTEIN CLDN6; PROTEIN FBN2; PROTEIN RBP1; PROTEIN TFPI2; PROTEIN TMEFF2; RETINOL BINDING PROTEIN 4; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; CELLULAR RETINOL BINDING PROTEIN; CLAUDIN 6; FIBRILLIN; GLYCOPROTEIN; MEMBRANE PROTEIN; PLACENTA PROTEIN 5; PLASMA RETINOL BINDING PROTEIN; RBP1 PROTEIN, HUMAN; RBP4 PROTEIN, HUMAN; TISSUE-FACTOR-PATHWAY INHIBITOR 2; TMEFF2 PROTEIN, HUMAN; TUMOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; DNA METHYLATION; ESOPHAGUS CARCINOMA; GENE EXPRESSION; GENE IDENTIFICATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; ESOPHAGUS TUMOR; GENETICS; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; GENE SILENCING; GLYCOPROTEINS; HUMANS; MEMBRANE PROTEINS; MICROFILAMENT PROTEINS; NEOPLASM PROTEINS; RETINOL-BINDING PROTEINS, CELLULAR; RETINOL-BINDING PROTEINS, PLASMA;

EID: 67449100578     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000325     Document Type: Article

References (23)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Sant M, Aareleid T, Berrino F, et al: EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. Ann Oncol 14 (Suppl. 5): V61-V118, 2003.
3. Botterweck AA, Schouten LJ, Volovics A, Dorant E and van Den Brandt PA: Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29: 645-654, 2000.
4. Pohl H and Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97: 142-146, 2005.
5. Lord RV, Law MG, Ward RL, Giles GG, Thomas RJ and Thursfield V: Rising incidence of oesophageal adenocarcinoma in men in Australia. J Gastroenterol Hepatol 13: 356-362, 1998.
6. Vizcaino AP, Moreno V, Lambert R and Parkin DM: Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 99: 860-868, 2002.
7. Dawsey SM, Lewin KJ, Wang GQ, et al: Squamous esophageal histology and subsequent risk of squamous cell carcinoma of the esophagus. A prospective follow-up study from Linxian, P.R. China. Cancer 74: 1686-1692, 1994.
8. Bird A: The essentials of DNA methylation. Cell 70: 5-8, 1992.
9. Smith E, Nancarrow DJ, Pavey S, et al: Gene promoter methylation of ID4 And ARL4D in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 130 (Suppl. 2): A565, 2006.
10. Smith E, De Young NJ, Ruszkiewicz AR, Devitt PG, Jamieson GG and Drew PA: Novel aberrantly methylated genes in esophageal adenocarcinoma. Gastroenterology 132 (Suppl. 2): 322, 2007.
11. Shimada Y, Imamura M, Wagata T, Yamaguchi N and Tobe T: Characterization of 21 newly established esophageal cancer cell lines. Cancer 69: 277-284, 1992.
12. Tsunoda S, Okumura T, Ito T, et al: Significance of nerve growth factor overexpression and its autocrine loop in esophageal squamous cell carcinoma. Br J Cancer 95: 322-330, 2006.
13. Smith E, Drew PA, Tian ZQ, et al: Metallothionien 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation. Mol Cancer 4: 42, 2005.
14. Smith E, Bianco-Miotto T, Drew P and Watson D: Method for optimizing methylation-specific PCR. BioTechniques 35: 32-33, 2003.
15. Smith E, De Young NJ, Tian ZQ, et al: Methylation of TIMP3 in esophageal squamous cell carcinoma. World J Gastroenterol 14: 203-210, 2008.
16. Chomczynski P: A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. BioTechniques 15: 532-534, 536-537, 1993.
17. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003.
18. Esteller M: Relevance of DNA methylation in the management of cancer. Lancet Oncol 4: 351-358, 2003.
19. Darnton SJ, Hardie LJ, Muc RS, Wild CP and Casson AG: Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: loss of expression correlates with poor prognosis. Int J Cancer 115: 351-358, 2005.
20. Eads CA, Lord RV, Wickramasinghe K, et al: Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 61: 3410-3418, 2001.
21. Schulmann K, Sterian A, Berki A, et al: Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 24: 4138-4148, 2005.
22. Kominsky SL: Claudins: emerging targets for cancer therapy. Expert Rev Mol Med 8: 1-11, 2006.
23. Arabzadeh A, Troy TC and Turksen K: Changes in the distribution pattern of Claudin tight junction proteins during the progression of mouse skin tumorigenesis. BMC Cancer 7: 196, 2007.